Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes among adults with Langerhans cell histiocytosis.
Goyal G, Acosta-Medina AA, Abeykoon JP, Dai C, Ravindran A, Vassallo R, Ryu JH, Shah MV, Bennani NN, Young JR, Bach CR, Ruan GJ, Zanwar S, Tobin WO, Koster MJ, Davidge-Pitts CJ, Gruber LM, Dasari S, Rech KL, Go RS. Goyal G, et al. Among authors: abeykoon jp. Blood Adv. 2023 Nov 14;7(21):6568-6578. doi: 10.1182/bloodadvances.2023010706. Blood Adv. 2023. PMID: 37698994 Free PMC article.
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, Kourelis T, King RL, Reeder CB, Leung N, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, Dispenzieri A, Lacy MQ, Go RS, Lin Y, Gonsalves WI, Warsame R, Lust JA, Rajkumar SV, Ansell SM, Kapoor P. Paludo J, et al. Among authors: abeykoon jp. Br J Haematol. 2017 Oct;179(1):98-105. doi: 10.1111/bjh.14826. Epub 2017 Aug 8. Br J Haematol. 2017. PMID: 28786474 Free article.
Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
Lakshman A, Abeykoon JP, Kumar SK, Rajkumar SV, Dingli D, Buadi FK, Gonsalves WI, Leung N, Dispenzieri A, Kourelis TV, Go RS, Lacy MQ, Hobbs MA, Lin Y, Warsame R, Lust J, Fonder AL, Hwa YL, Hayman SR, Russell SJ, Kyle RA, Gertz MA, Kapoor P. Lakshman A, et al. Among authors: abeykoon jp. Am J Hematol. 2017 Nov;92(11):1146-1155. doi: 10.1002/ajh.24883. Epub 2017 Sep 8. Am J Hematol. 2017. PMID: 28799231 Free article.
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, Lin Y, Thompson CA, Hayman SR, Kyle RA, Kumar SK, Kapoor P. Abeykoon JP, et al. Am J Hematol. 2018 Feb;93(2):187-194. doi: 10.1002/ajh.24955. Epub 2017 Nov 17. Am J Hematol. 2018. PMID: 29080258 Free article.
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P. Paludo J, et al. Among authors: abeykoon jp. Ann Hematol. 2018 Aug;97(8):1417-1425. doi: 10.1007/s00277-018-3311-z. Epub 2018 Apr 3. Ann Hematol. 2018. PMID: 29610969
Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.
Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P. Abeykoon JP, et al. Am J Hematol. 2018 Nov;93(11):1384-1393. doi: 10.1002/ajh.25254. Epub 2018 Oct 2. Am J Hematol. 2018. PMID: 30121949 Free article.
Ixazomib: a novel drug for multiple myeloma.
Zanwar S, Abeykoon JP, Kapoor P. Zanwar S, et al. Among authors: abeykoon jp. Expert Rev Hematol. 2018 Oct;11(10):761-771. doi: 10.1080/17474086.2018.1518129. Expert Rev Hematol. 2018. PMID: 30173621 Review.
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis.
Abeykoon JP, Zanwar S, Dispenzieri A, Gertz MA, Leung N, Kourelis T, Gonsalves W, Muchtar E, Dingli D, Lacy MQ, Hayman SR, Buadi F, Warsame R, Kyle RA, Rajkumar V, Kumar S, Kapoor P. Abeykoon JP, et al. Leukemia. 2019 Feb;33(2):531-536. doi: 10.1038/s41375-018-0262-2. Epub 2018 Sep 28. Leukemia. 2019. PMID: 30267007 No abstract available.
Primary systemic amyloidosis in patients with Waldenström macroglobulinemia.
Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P. Zanwar S, et al. Among authors: abeykoon jp. Leukemia. 2019 Mar;33(3):790-794. doi: 10.1038/s41375-018-0286-7. Epub 2018 Oct 12. Leukemia. 2019. PMID: 30315235 No abstract available.
91 results